THE TREATMENT OF THE GRAFT AND THE RECIPIENT WITH Α-LIPOIC ACID IMPROVE THE PATIENT CONDITIONS BY REDUCING THE DIALYSIS REQUIREMENTS

AMBROSI, NELLA; MARDIROSIAN M; CHULUYAN EDUARDO; CARO FIORELLA; OSELLA F; INCARDONA CLAUDIO; GUERRIERI DIEGO; CASADEI DOMINGO

Congreso; Reunión Conjunta SAIC SAI SAFIS 2018; 2018

A previous pilot clinic trial had showed that treatment of the donorand recipient with α-lipoc acid (ALA), protects against the ischemiareperfusion injury in simultaneous kidney-pancreas transplantation.Therefore, the aim of this work was to evaluate whether the administration of ALA could improve early clinical outcomes of kidney transplant patients.The study included 68 kidney transplant patients. They were dividedin two groups. In the group 1, recipients were treated with placebo (24 patients) and received a graft perfused with placebo. In thegroup 2, recipients received 600 mg of ALA i.v immediately previousto the surgical procedure and the graft was perfused with 600 mg ofALA 1 hour before the surgery (44 patients). Blood samples wereobtained at different moments, before and after the transplant andearly clinical outcomes parameters were analyzed.At first day after transplantation, ALA-treated group had lower plasmatic urea levels (p=0.001) and a glomerular filtration rate with atrend to be higher than control group, however, these results werenot maintained in the time. Concurrently, the presence of delay graftfunction (DGF), was not different between both groups. Remarkably,when the number of patients requiring dialysis was analyzed dayby day in the first week post-transplant, a lower percentage of dialyzed patients per day could be observed in the group treated withALA with respect to the control group. Finally, there was a tendencyto have fewer episodes of rejection in the treated group vs controlgroup (p = 0.07). Overall, this study shows that even though ALAtreatment could not avoid DGF, it can improve the patient conditionsby reducing the dialysis requirements